Aeson® Artificial Heart
End-stage biventricular heart failure (Bridge-to-Transplant)
Key Facts
About Carmat
Carmat's mission is to develop and commercialize a permanent, fully implantable artificial heart to address the unmet need in end-stage biventricular heart failure. Its key achievement is the Aeson® device, which has obtained CE Mark approval in Europe and is under investigation in a pivotal U.S. study (EFICAS). The company's strategy is to methodically advance clinical validation, secure regulatory approvals in key markets, and establish the infrastructure for commercial rollout, positioning Aeson® as a transformative alternative to heart transplantation.
View full company profileAbout Carmat
Carmat's mission is to develop and commercialize a permanent, fully implantable artificial heart to address the unmet need in end-stage biventricular heart failure. Its key achievement is the Aeson® device, which has obtained CE Mark approval in Europe and is under investigation in a pivotal U.S. study (EFICAS). The company's strategy is to methodically advance clinical validation, secure regulatory approvals in key markets, and establish the infrastructure for commercial rollout, positioning Aeson® as a transformative alternative to heart transplantation.
View full company profileAbout Carmat
Carmat's mission is to develop and commercialize a permanent, fully implantable artificial heart to address the unmet need in end-stage biventricular heart failure. Its key achievement is the Aeson® device, which has obtained CE Mark approval in Europe and is under investigation in a pivotal U.S. study (EFICAS). The company's strategy is to methodically advance clinical validation, secure regulatory approvals in key markets, and establish the infrastructure for commercial rollout, positioning Aeson® as a transformative alternative to heart transplantation.
View full company profile